Global Psychedelic API Market Size is valued at US$ 3.5 Bn in 2025 and is predicted to reach US$ 10.5 Bn by the year 2034 at an 12.8% CAGR during the forecast period for 2025-2034.
Psychedelic APIs are mostly utilized as crucial components in the creation of contemporary treatments for mental health issues like anxiety disorders, PTSD, addiction, and depression. They are used by pharmaceutical companies to develop controlled formulations for clinical trials, where the goal is to improve cases that are resistant to therapy. Additionally, they are used in neurobiology research to comprehend cognitive flexibility and consciousness.
These APIs are crucial in developing safer, standardized, and scientifically supported medical treatments as interest in psychedelic-assisted therapy increases. Researchers employ these active ingredients to study their effects on mood, memory, and emotional processing circuits in the brain. The global market for psychedelic API is expanding due to ,more clinical studies demonstrate positive outcomes for treating disorders including severe depression, PTSD, and addiction that don't react well to conventional psychiatric medications.
The rising need for more effective treatments for mental-health disorders, especially depression, PTSD, and addiction is another element propelling the psychedelic API market. The psychedelic API market is expanding because rising public awareness and desire for alternative mental health treatments. The WHO Over 1 billion individuals worldwide suffer from mental, neurological, or drug use illnesses; in 2023, 15% of the global population is predicted to have had a mental disorder. However, strict regulations because many psychedelic compounds are still categorized as prohibited substances, which takes time for research and authorization are some of the obstacles impeding the growth of the psychedelic API sector. Over the course of the forecast period, opportunities for the Psychedelic API market will be created by increasing investments in clinical infrastructure and local active pharmaceutical ingredient (API) synthesis capabilities.
Which are the Leading Players in Psychedelic API Market?
· Compass Pathways
· MindMed
· Atai Life Sciences
· Cybin Inc
· Usona Institute
· Delic Holdings Inc.
· Havn Life Sciences
· Beckley Psytech
· Psilera Inc
· NeonMind Biosciences
· Others
The psychedelic API market is segmented by molecule / class, source / synthesis route, form / solid-state & grade, contracting model, and end use. By molecule / class, the market is segmented into psilocybin / psilocin, MDMA, MDMA base, MDMA salts, lysergide / LSD, tryptamines, Iboga alkaloids (ibogaine, noribogaine), ketamine class, next-gen 5-ht2a modulators / psychoplastogens. Psilocybin / psilocin is further classified into psilocybin, psilocin, deuterated psilocin, and psilocin prodrugs. Lysergide / LSD is categorized into lysergide and lysergic acid derivatives. Tryptamines is sub-segmented into DMT and 5-meo-dmt. Iboga alkaloids is classified into ibogaine and noribogaine. Ketamine class is categorized into racemic ketamine and esketamine, whereas next-gen 5-ht2a modulators / psychoplastoge in classified into non-hallucinogenic modulators and short-acting serotonergics. By source / synthesis route, the market is segmented into fully synthetic, biosynthetic / fermentation, engineered microbial pathways and botanical / fungal extraction. Engineered microbial pathways is further classified into fungal / mycelial fermentation and semi-synthetic. By form / solid-state & grade, the market is segmented into salt forms, base forms, polymorph / crystal form, and micronized / particle-size controlled grades. By contracting model, the market is segmented into CDMO outsourcing (development to scale), captive / in-house API, dual-sourcing / tech transfer, and pathway / IP licensing (biosynthesis). By end use, the market is segmented into branded Rx developers / sponsors, clinic networks / licensed compounding, state-regulated service providers, and academic / investigator-initiated programs.
The ketamine segment led the psychedelic API market in 2024. This convergence is because of strong regulatory support and therapeutic acceptance. In order to facilitate the approval of the esketamine class, the FDA has expedited the creation of commercial infrastructure. The sector growth is being fulfilled by the FDA's current authorization of ketamine for treatment-resistant depression. Demand is driven by the widespread usage of ketamine in the treatment of anxiety disorders, depression, and PTSD. Rapid-acting antidepressant qualities, robust manufacturing infrastructure, and broad clinical acceptance characterize this class.
Salt forms represent the largest and fastest-growing segment, driven by increasing novel therapeutic designations and rising clinical trial activity. These forms offer enhanced stability, improved bioavailability, and greater efficiency in manufacturing processes. By optimizing key physicochemical properties, salt forms help create pharmaceutical products that are more suitable for both clinical development and commercial-scale production. For drug manufacturers, they ensure that synthetic APIs remain consistently pure, high quality, and easily scalable, making them a preferred choice across a wide range of pharmaceutical applications.
North America dominated the psychedelic API market in 2024. The United States is at the forefront of this expansion. This is due to the The region leads in clinical research, government-approved trials, and investment in mental-health innovations are attributed to this. High-quality APIs are in constant demand due to the active development of psychedelic-based medicines by universities, biotech companies, and pharmaceutical companies.North America's dominance is further reinforced by robust funding, cutting-edge labs, and growing interest in alternative therapies.
Rising prevalence of addiction, stress disorders, and depression is becoming more and more common in the Asia-Pacific area, the psychedelic API market is expanding at the strongest and fastest rate in this region. Additionally, number of nations that are progressively opening doors to innovation in mental health and enhancing their research capacities. The region has a robust production capability for high-purity APIs because to rising investment in biotech manufacturing. The market is expanding quickly as more businesses enter the market as local awareness grows and rules gradually change.
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Psychedelic API Market Snapshot
Chapter 4. Global Psychedelic API Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2025-2034
4.8. Competitive Landscape & Market Share Analysis, By Key Player (2024)
4.9. Use/impact of AI on Psychedelic API Market Industry Trends
4.10. Global Psychedelic API Market Penetration & Growth Prospect Mapping (US$ Mn), 2024-2034
Chapter 5. Psychedelic API Market Segmentation 1: By Molecule / Class, Estimates & Trend Analysis
5.1. Market Share by Molecule / Class, 2024 & 2034
5.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Molecule / Class:
5.2.1. Psilocybin / Psilocin
5.2.1.1. Psilocybin
5.2.1.2. Psilocin
5.2.1.3. Deuterated psilocin
5.2.1.4. Psilocin prodrugs
5.2.2. MDMA
5.2.3. MDMA base
5.2.4. MDMA salts
5.2.5. Lysergide / LSD
5.2.5.1. Lysergide
5.2.5.2. Lysergic acid derivatives
5.2.6. Tryptamines
5.2.6.1. DMT
5.2.6.2. 5-MeO-DMT
5.2.7. Iboga Alkaloids
5.2.7.1. Ibogaine
5.2.7.2. Noribogaine
5.2.8. Ketamine Class
5.2.8.1. Racemic ketamine
5.2.8.2. Esketamine
5.2.9. Next-gen 5-HT2A modulators / psychoplastogens
5.2.9.1. Non-hallucinogenic modulators
5.2.9.2. Short-acting serotonergics
Chapter 6. Psychedelic API Market Segmentation 2: By Source / Synthesis Route, Estimates & Trend Analysis
6.1. Market Share by Source / Synthesis Route, 2024 & 2034
6.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Source / Synthesis Route:
6.2.1. Fully synthetic
6.2.2. Biosynthetic / fermentation
6.2.3. Engineered microbial pathways
6.2.3.1. Fungal / mycelial fermentation
6.2.3.2. Semi-synthetic
6.2.4. Botanical / fungal extraction
Chapter 7. Psychedelic API Market Segmentation 3: By Form / Solid-State & Grade, Estimates & Trend Analysis
7.1. Market Share by Form / Solid-State & Grade, 2024 & 2034
7.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Form / Solid-State & Grade:
7.2.1. Salt forms
7.2.2. Base forms
7.2.3. Polymorph / crystal form
7.2.4. Micronized / particle-size controlled grades
Chapter 8. Psychedelic API Market Segmentation 4: By Contracting Model, Estimates & Trend Analysis
8.1. Market Share by Contracting Model, 2024 & 2034
8.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Contracting Model:
8.2.1. CDMO outsourcing (development to scale)
8.2.2. Captive / in-house API
8.2.3. Dual-sourcing / tech transfer
8.2.4. Pathway / IP licensing (biosynthesis)
Chapter 9. Psychedelic API Market Segmentation 5: By End Use, Estimates & Trend Analysis
9.1. Market Share by End Use, 2024 & 2034
9.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following End Use:
9.2.1. Branded Rx developers / sponsors
9.2.2. Clinic networks / licensed compounding
9.2.3. State-regulated service providers
9.2.4. Academic / investigator-initiated programs
Chapter 10. Psychedelic API Market Segmentation 6: Regional Estimates & Trend Analysis
10.1. Global Psychedelic API Market, Regional Snapshot 2024 & 2034
10.2. North America
10.2.1. North America Psychedelic API Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
10.2.1.1. US
10.2.1.2. Canada
10.2.2. North America Psychedelic API Market Revenue (US$ Million) Estimates and Forecasts by Molecule / Class, 2021-2034
10.2.3. North America Psychedelic API Market Revenue (US$ Million) Estimates and Forecasts by Source / Synthesis Route, 2021-2034
10.2.4. North America Psychedelic API Market Revenue (US$ Million) Estimates and Forecasts by Form / Solid-State & Grade, 2021-2034
10.2.5. North America Psychedelic API Market Revenue (US$ Million) Estimates and Forecasts by Component, 2021-2034
10.2.6. North America Psychedelic API Market Revenue (US$ Million) Estimates and Forecasts by Contracting Model, 2021-2034
10.2.7. North America Psychedelic API Market Revenue (US$ Million) Estimates and Forecasts by End Use, 2021-2034
10.3. Europe
10.3.1. Europe Psychedelic API Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
10.3.1.1. Germany
10.3.1.2. U.K.
10.3.1.3. France
10.3.1.4. Italy
10.3.1.5. Spain
10.3.1.6. Rest of Europe
10.3.2. Europe Psychedelic API Market Revenue (US$ Million) Estimates and Forecasts by Molecule / Class, 2021-2034
10.3.3. Europe Psychedelic API Market Revenue (US$ Million) Estimates and Forecasts by Source / Synthesis Route, 2021-2034
10.3.4. Europe Psychedelic API Market Revenue (US$ Million) Estimates and Forecasts by Form / Solid-State & Grade, 2021-2034
10.3.5. Europe Psychedelic API Market Revenue (US$ Million) Estimates and Forecasts by Contracting Model, 2021-2034
10.3.6. Europe Psychedelic API Market Revenue (US$ Million) Estimates and Forecasts by End Use, 2021-2034
10.4. Asia Pacific
10.4.1. Asia Pacific Psychedelic API Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
10.4.1.1. India
10.4.1.2. China
10.4.1.3. Japan
10.4.1.4. Australia
10.4.1.5. South Korea
10.4.1.6. Hong Kong
10.4.1.7. Southeast Asia
10.4.1.8. Rest of Asia Pacific
10.4.2. Asia Pacific Psychedelic API Market Revenue (US$ Million) Estimates and Forecasts by Molecule / Class, 2021-2034
10.4.3. Asia Pacific Psychedelic API Market Revenue (US$ Million) Estimates and Forecasts by Source / Synthesis Route, 2021-2034
10.4.4. Asia Pacific Psychedelic API Market Revenue (US$ Million) Estimates and Forecasts by Form / Solid-State & Grade, 2021-2034
10.4.5. Asia Pacific Psychedelic API Market Revenue (US$ Million) Estimates and Forecasts by Contracting Model, 2021-2034
10.4.6. Asia Pacific Psychedelic API Market Revenue (US$ Million) Estimates and Forecasts by End Use, 2021-2034
10.5. Latin America
10.5.1. Latin America Psychedelic API Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
10.5.1.1. Brazil
10.5.1.2. Mexico
10.5.1.3. Rest of Latin America
10.5.2. Latin America Psychedelic API Market Revenue (US$ Million) Estimates and Forecasts by Molecule / Class, 2021-2034
10.5.3. Latin America Psychedelic API Market Revenue (US$ Million) Estimates and Forecasts by Source / Synthesis Route, 2021-2034
10.5.4. Latin America Psychedelic API Market Revenue (US$ Million) Estimates and Forecasts by Form / Solid-State & Grade, 2021-2034
10.5.5. Latin America Psychedelic API Market Revenue (US$ Million) Estimates and Forecasts by Contracting Model, 2021-2034
10.5.6. Latin America Psychedelic API Market Revenue (US$ Million) Estimates and Forecasts by End Use, 2021-2034
10.6. Middle East & Africa
10.6.1. Middle East & Africa Wind Turbine Rotor Blade Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
10.6.1.1. GCC Countries
10.6.1.2. Israel
10.6.1.3. South Africa
10.6.1.4. Rest of Middle East and Africa
10.6.2. Middle East & Africa Psychedelic API Market Revenue (US$ Million) Estimates and Forecasts by Molecule / Class, 2021-2034
10.6.3. Middle East & Africa Psychedelic API Market Revenue (US$ Million) Estimates and Forecasts by Source / Synthesis Route, 2021-2034
10.6.4. Middle East & Africa Psychedelic API Market Revenue (US$ Million) Estimates and Forecasts by Form / Solid-State & Grade, 2021-2034
10.6.5. Middle East & Africa Psychedelic API Market Revenue (US$ Million) Estimates and Forecasts by Contracting Model, 2021-2034
10.6.6. Middle East & Africa Psychedelic API Market Revenue (US$ Million) Estimates and Forecasts by End Use, 2021-2034
Chapter 11. Competitive Landscape
11.1. Major Mergers and Acquisitions/Strategic Alliances
11.2. Company Profiles
11.2.1. Compass Pathways
11.2.1.1. Business Overview
11.2.1.2. Key Contracting Model /Service Overview
11.2.1.3. Financial Performance
11.2.1.4. Geographical Presence
11.2.1.5. Recent Developments with Business Strategy
11.2.2. MindMed (Mind Medicine Inc.)
11.2.3. Atai Life Sciences
11.2.4. Cybin Inc
11.2.5. Usona Institute
11.2.6. Delic Holdings Inc
11.2.7. Havn Life Sciences
11.2.8. Beckley Psytech
11.2.9. Psilera Inc
11.2.10. NeonMind Biosciences
11.2.11. Seelos Therapeutics
11.2.12. MINDCURE Health Inc
11.2.13. Ehave Inc
11.2.14. Silo Wellness Inc.
11.2.15. Eleusis
Psychedelic API Market by Molecule / Class
· Psilocybin / Psilocin
o Psilocybin
o Psilocin
o Deuterated psilocin
o Psilocin prodrugs
· MDMA
· MDMA base
· MDMA salts
· Lysergide / LSD
o Lysergide
o Lysergic acid derivatives
· Tryptamines
o DMT
o 5-MeO-DMT
· Iboga Alkaloids
o Ibogaine
o Noribogaine
· Ketamine Class
o Racemic ketamine
o Esketamine
· Next-gen 5-HT2A modulators / psychoplastogens
o Non-hallucinogenic modulators
o Short-acting serotonergics
Psychedelic API Market by Source / Synthesis Route
· Fully synthetic
· Biosynthetic / fermentation
· Engineered microbial pathways
o Fungal / mycelial fermentation
o Semi-synthetic
· Botanical / fungal extraction
Psychedelic API Market by Form / Solid-State & Grade
· Salt forms
· Base forms
· Polymorph / crystal form
· Micronized / particle-size controlled grades
Psychedelic API Market by Contracting Model
· CDMO outsourcing (development to scale)
· Captive / in-house API
· Dual-sourcing / tech transfer
· Pathway / IP licensing (biosynthesis)
Psychedelic API Market by End Use
· Branded Rx developers / sponsors
· Clinic networks / licensed compounding
· State-regulated service providers
· Academic / investigator-initiated programs
Psychedelic API Market by Region
North America-
· The US
· Canada
Europe-
· Germany
· The UK
· France
· Italy
· Spain
· Rest of Europe
Asia-Pacific-
· China
· Japan
· India
· South Korea
· Southeast Asia
· Rest of Asia Pacific
Latin America-
· Brazil
· Argentina
· Mexico
· Rest of Latin America
Middle East & Africa-
· GCC Countries
· South Africa
· Rest of the Middle East and Africa